Newcastle Neurosurgery Clinical Trials Unit

Neurosurgical Clinical Trial Unit

Neurosurgical Clinical Trial Unit - ARUBA


click on the logo to go to the relevant external trial webpage



International randomised trial of unruptured brain arteriovenous malformations comparing intervention with conservative treatment.

ARUBA's goal is to test the null hypothesis that treatment, by means of interventional procedures, surgery, or radiotherapy offers no difference in the risk of death or symptomatic stroke, and no better functional outcome than does conservative management at five years from discovery of an unruptured brain arteriovenous malformation (BAVM).

Brief inclusion / exclusion criteria


  • Unruptured BAVM diagnosed by MRI/MRA, CTA and/or angiogram
  • Patient must be 18 years or older
  • Patient must have signed the Informed Consent Form

  • Exclusion:

  • Evidence or recent or previous haemorrhage
  • Patient has received BAVM therapy previously - endovascular, surgical or radiotherapy
  • BAVM is deemed untreatable or contraindications for interventional therapy
  • Baseline Rankin of ≥ 2
  • Concomitant disease reducing life expectancy to less than 10 years
  • Uncorrectable coagulopathy - INR > 1.5
  • Pregnancy
  • Multiple-foci BAVMs
  • Patient has known allergy against iodine contrast agents
  • Staff Involved

    Principal Investigators:

    Dr J.P. Mohr (New York)
    Dr. C. Stapf (Paris)

    Prof. A.D. Mendelow
    Dr. P. Dorman

    Assigned Registrar: Damian Holliman


    Last updated 19 Jan 2009
    © NCTU Email: